Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the Growth Rate of the Seasonal Influenza Market Shape Industry Trends by 2034?

Over the past few years, the market size of seasonal influenza has grown significantly. It is projected to increase from $8.41 billion in 2024 to $9.88 billion in 2025, with a compound annual growth rate (CAGR) of 17.4%. The noteworthy growth in the historic period is due to factors such as an increased incidence of influenza, a growing elderly population, increased prevalence of infectious and chronic diseases, escalating burden of influenza-related illnesses, and a surge in respiratory infections.

Expectations are high for the expansion of the seasonal influenza market, with predictions of rapid growth in the coming years. The projections show the market reaching $18.55 billion by 2029, reflecting a compound annual growth rate (CAGR) of 17.1%. This projected surge during the forecast period is linked to factors such as the rising demand for oral drug solutions, growth in research and development activities, increased vaccination rates, advancements in healthcare infrastructure, and higher demand in retail pharmacies. Key trends expected to shape the forecast period include progress in treatment methods, technological advancement, developments in vaccine and mRNA technology, and the use of digital health solutions for tracking and diagnosis.

What Industry-Specific Factors Are Fueling the Growth of the Seasonal Influenza Market?

The escalating instances of respiratory infections are anticipated to drive the expansion of the seasonal influenza market in upcoming years. Respiratory infections, caused by viruses or bacteria, impact the respiratory system, including the sinuses, throat, airways, or lungs. The rising frequency of these infections is attributed to air pollution, shifting climates, compromised immune responses, and easy viral transmission in overcrowded or poorly ventilated spaces. Seasonal influenza treatment aids in curbing or lessening the impact of respiratory infections in various ways, primarily by targeting the influenza virus and controlling symptoms leading to secondary infections. For example, data from the UK Health Security Agency, a UK-based government organization, revealed that in October 2024, the number of tuberculosis (TB) cases (also a respiratory infection caused by the bacterium Mycobacterium tuberculosis) in England saw a 10.7% yearly increase in 2023, from 4,380 cases in 2022 to 4,850 cases. Hence, the uptick in respiratory infections is predicted to fuel the expansion of the seasonal influenza market.

Request Your Free Seasonal Influenza Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=21285&type=smp

Who Are the Key Market Players Influencing the Growth of the Seasonal Influenza Industry?

Major companies operating in the seasonal influenza market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Merck KGaA, Moderna Inc., Boehringer Ingelheim International GmbH, Sinovac Biotech Ltd., Daiichi Sankyo Company Limited, CSL Limited, Genentech Inc., Shionogi & Co. Ltd., Emergent BioSolutions Inc., Novavax Inc., BioCryst Pharmaceuticals Inc., Bharat Biotech International Limited, Vaxart Inc., Inovio Pharmaceuticals Inc., SK bioscience Co. Ltd., Mitsubishi Tanabe Pharma Corporation, FluGen Inc., Altimmune Inc.

What Key Market Trends Are Shaping the Future of the Seasonal Influenza Industry?

The seasonal influenza market is seeing significant attention from leading companies in the push for advancements in treatments. A prime example of the focus is on combination vaccines, designed to fortify immunity by targeting several strains of the virus at once, thus enhancing the treatment’s effectiveness and minimizing the need for reiterated vaccinations. The benefit of combination vaccines is their inherent ability to protect against several diseases or strains via a single injection, which decreases the necessary shot count for immunization. An illustration of this advancement was the announcement in October 2023, by Moderna, Inc., a biotechnology establishment based in the United States, of optimistic interim Phase 1/2 trial results for mRNA-1083. This investigational combination vaccine, aimed at influenza and COVID-19, is designed to optimize compliance, simplify administration, and enhance convenience for patients and healthcare systems. mRNA-1083 is currently being assessed for its safety and immunogenicity against conventional flu vaccines like Fluarix (for ages 50-64) and Fluzone HD (for ages 65-79). It is also in comparative trials against the Spikevax booster.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/seasonal-influenza-global-market-report

What Are the Main Segments of the Seasonal Influenza Market, and How Are They Evolving?

The seasonal influenza market covered in this report is segmented –

1) By Type: Influenza A Virus, Influenza B Virus, Influenza C Virus, Influenza D Virus

2) By Route Of Administration: Parenteral, Oral, Other Route Of Administrations

3) By Distribution Channel: Hospital, Government and institutional supply, Pharmacy, Online

4) By Treatment: Antiviral, Neuraminidase Inhibitors, Vaccination, Other Treatments

Subsegments:

1) By Influenza A Virus: Subtype H1N1, Subtype H3N2, Other Subtypes

2) By Influenza B Virus: Lineage Victoria, Lineage Yamagata

3) By Influenza C Virus: Seasonal C Virus, Non-seasonal C Virus

4) By Influenza D Virus: Animal-associated Influenza D

Which Regions Are Emerging as Leaders in the Seasonal Influenza Market?

North America was the largest region in the seasonal influenza market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the seasonal influenza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Defining Features of the Seasonal Influenza Market?

Seasonal influenza, commonly known as the flu, is a contagious respiratory infection caused by influenza viruses that circulate globally, primarily during specific seasons (typically fall and winter in temperate regions). It spreads through respiratory droplets when an infected person coughs, sneezes, or talks. Seasonal influenza leads to widespread illness and can result in serious complications, particularly for vulnerable populations such as the elderly and those with weakened immune systems.

Browse Through More Similar Reports By The Business Research Company:

Hormone Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report

Biosimilar Growth Hormones Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report

Biosimilar Hormones Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: